LODESTONE BIOMEDICAL
OperatingLodestone Biomedical Inc.
Biotech · Biotech · Lebanon, NH · Founded 2015
Immune response indication system
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Class A common stock | 9,551,145 | — | 96.0% | — |
| Class B common stock | 400,000 | — | 4.02% | — |
| Total | 9,951,145 | 100% |
Sold to the crowd
- Reg CF · Nov 2024152,298 shares at $1.47$223.9K· 106 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
9 people
Sol is an inventor and entrepreneur with over 20 years experience in biomedical research and product development. He is also an Associate Professor of Engineering at Dartmouth where he is a Member of the Translational Engineering in Cancer Research Program at the Dartmouth-Hitchcock Medical Center. Sol has over 50 publications, 2500 citations, and holds 8 US patents.
Arti is Lodestone's subject matter expert in cancer biology, immunology, biomarkers, and implantable biosensors. She is also an Assistant Professor of Neurology at Geisel School of Medicine at Dartmouth where she is the Study Chair and PI on a multi-institutional clinical trial on cancer biomarkers. Arti directed all of Lodestone’s preclinical studies at the Dartmouth-Hitchcock Medical Center.
Hye Jung is an experienced chemist who specializes in organic and polymer synthesis, analytical chemistry, and biomaterials development. She excels in innovative process and product development. Hye Jung is responsible for the design, development and validation of functionalized magnetic nanoparticles at Lodestone.
Carmen is a dedicated researcher with extensive experience in designing and running preclinical experiments. At Lodestone he is responsible for implant design, miniaturization, and optimization. Currently Carmen is designing an automated production system for sterile assembly and validation testing of IRIS biosensors.
Christian is a biomedical engineer and co-inventor of Lodestone’s IRIS biosensor. He completed his PhD at the Physikalisch-Technische Bundesanstalt in Berlin, Germany focusing on the topic of quantitative detection of magnetic nanoparticles in biological samples.
John is the CFO and co-founder of S1 Biopharma, a developer of prescription therapeutics for under-treated CNS dysfunctions. Prior to that, John was a finance executive at Laureate Education and Fidelity Investments, where he had senior finance and FP&A roles overseeing multinational high-growth operating subsidiaries.
Rick is an entrepreneur and biomedical engineer with over 25 years of medical device commercialization experience. He is the founder and CEO of Simbex (Lebanon, NH), and was founding CEO of venture-funded iWalk (now BionX). He is a Fellow of the National Academy of Inventors, and holds 15 US patents, with 4 pending.
Throughout his forty-five-year career, Roland has developed a strong reputation as an internationally-respected Talent Development expert. He has led Human Resources globally in multiple sectors for global companies of varying complexity, and has successfully coached CEOs, Presidents, General Managers, and other business leaders from twenty countries.
Seth is a mechanical engineer with a background in mechanical design of heat exchangers and piping. He completed his Master of Engineering degree at the Thayer School of Engineering at Dartmouth. Seth focuses on the development of Lodestone's magnetic nanoparticle reader platforms and is currently developing the next generation of our preclinical system.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.